Welcome to our dedicated page for LMNX news (Ticker: LMNX), a resource for investors and traders seeking the latest updates and insights on LMNX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LMNX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LMNX's position in the market.
Middlesex Water Co. (MSEX) is set to join the S&P SmallCap 600 index on July 15, 2021, replacing Luminex Corp. (LMNX), which is being acquired by DiaSorin S.p.A. This change will be effective prior to the market's opening on that date. The addition of Middlesex Water underscores its growth and stability in the utilities sector, while Luminex's removal reflects the implications of its pending acquisition. The decision was made by S&P Dow Jones Indices, which oversees significant financial market indicators.
Luminex Corporation (Nasdaq:LMNX) announced a cash dividend of $0.10 per share for Q2 2021. This dividend is payable on July 8, 2021, to shareholders recorded as of the close on June 17, 2021. The announcement reflects the company's commitment to returning value to its shareholders while supporting its mission to provide reliable and timely solutions across various markets including clinical diagnostics and research.
DiaSorin has announced the acquisition of Luminex Corporation for USD 37.00 per share, totaling approximately USD 1.8 billion in an all-cash transaction. This purchase reflects a premium of 23.1% over Luminex's stock price before acquisition rumors. The deal aims to enhance DiaSorin's positioning in the molecular diagnostics field and broaden its U.S. market presence. The combined company is expected to generate around €1.25 billion in revenues and achieve cost synergies of USD 55 million within three years. The transaction is anticipated to close in Q3 2021, pending shareholder and regulatory approvals.
Luminex Corporation (NASDAQ: LMNX) submitted an Emergency Use Authorization application to the FDA for its new ARIES® Flu A/B & RSV+SARS-CoV-2 Assay. This multi-analyte respiratory panel targets Flu A/B, RSV, and SARS-CoV-2, allowing for quick diagnosis from a single test. Supported by BARDA funding, the assay promises results in about two hours on Luminex's ARIES® Systems and is expected to detect new variants of the coronavirus. The company aims to expand FDA-authorized assays for SARS-CoV-2, enhancing clinical care during respiratory infection outbreaks.
Luminex Corporation (NASDAQ: LMNX) has announced its participation at the 2021 Barclays Global Healthcare Conference on March 10, 2021, at 8:35 a.m. Eastern Time. Homi Shamir, Chairman, CEO & President, and Harriss Currie, Senior VP and CFO, will represent the company. A live webcast of the presentation will be accessible on the company's website and archived for six months. Luminex supports various sectors, including clinical diagnostics and biomedical research, providing timely, reliable solutions for advancing health.
Luminex Corporation (NASDAQ: LMNX) announced receiving Emergency Use Authorization (EUA) from the FDA for its expanded NxTAG® Respiratory Pathogen Panel, now including SARS-CoV-2, enhancing high-throughput testing capabilities. The NxTAG RPP can detect 19 viral and 2 bacterial targets, processing up to 96 samples in four hours. This advanced test aims to facilitate the differentiation of respiratory pathogens like COVID-19 and influenza. The NxTAG RPP demonstrates expected efficacy against new coronavirus variants. Additionally, a version of the assay received CE Mark in Europe.
Luminex Corporation (NASDAQ: LMNX) has secured $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to develop a respiratory panel test. This test will simultaneously detect Flu A/B, RSV, and SARS-CoV-2, which is crucial for clinical labs facing increased demand for respiratory illness testing. The ARIES® Systems can deliver results in under two hours, reducing the workload on labs. Luminex plans to request Emergency Use Authorization from the FDA for the new assay, enhancing their portfolio in the ongoing fight against respiratory diseases.
Luminex Corporation (Nasdaq: LMNX) reported record revenue for Q4 2020 of $111.4 million, a 23% increase from Q4 2019, and a yearly total of $417.4 million, up 25%. Gross margins improved to 58% for Q4 and 59% for the full year. Operating income surged 250% to $10.5 million for Q4, with a net income of $15.2 million for the year, a substantial turnaround from a $3.8 million loss in 2019. The company reaffirms 2021 revenue expectations of approximately $480 million, driven by ARIES® assay sales and expanded capabilities.
Luminex Corporation (Nasdaq:LMNX) announced a cash dividend of $0.10 per share for Q1 2021. This dividend will be payable on April 15, 2021, to stockholders recorded as of the close of business on March 25, 2021. The company focuses on delivering reliable and timely solutions in various markets such as clinical diagnostics and drug discovery, emphasizing its commitment to advancing health.
Luminex Corporation (NASDAQ: LMNX) will report its financial results for Q4 ending December 31, 2020, on February 8, 2021. A press release with the results will be issued after trading closes on that date. The company will host a conference call at 5:00 PM Eastern Time on February 8, 2021, to discuss the operating highlights and financial outcomes. Interested parties can access the live webcast on Luminex's website. The company aims to deliver reliable and actionable answers across various markets, including clinical diagnostics and biomedical research.
